Spyre Therapeutics Files 8-K

Ticker: SYRE · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1636282

Spyre Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpyre Therapeutics, Inc. (SYRE)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $603 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, operations, financials

TL;DR

Spyre Therapeutics (fka Aeglea) filed an 8-K on Jan 13, 2025, updating on ops & financials.

AI Summary

Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K on January 13, 2025, reporting on its results of operations, other events, and financial statements. The company, incorporated in Delaware, is in the pharmaceutical preparations industry.

Why It Matters

This filing provides an update on Spyre Therapeutics' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant events but doesn't inherently introduce new risks.

Key Players & Entities

  • Spyre Therapeutics, Inc. (company) — Registrant
  • Aeglea BioTherapeutics, Inc. (company) — Former Company Name
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 221 Crescent Street Building 23 Suite 105 (address) — Principal Executive Offices
  • Waltham, MA 02453 (address) — Principal Executive Offices Location

FAQ

What is the primary business of Spyre Therapeutics, Inc.?

Spyre Therapeutics, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on January 13, 2025.

What was Spyre Therapeutics, Inc. formerly known as?

Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc.

Where are Spyre Therapeutics, Inc.'s principal executive offices located?

Spyre Therapeutics, Inc.'s principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.

What is the state of incorporation for Spyre Therapeutics, Inc.?

Spyre Therapeutics, Inc. is incorporated in Delaware.

Filing Stats: 656 words · 3 min read · ~2 pages · Grade level 13.1 · Accepted 2025-01-13 08:08:20

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share SYRE The Nasdaq
  • $603 million — cts to report that it had approximately $603 million of cash, cash equivalents and marketabl

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of the Company, dated January 13, 2025 99.2 Corporate Presentation (January 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SPYRE THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Cameron Turtle Cameron Turtle Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.